Cardiac Arrest (CA)MOPCASNCT07090577
Multiomics Profiling of CSF in Cardiac Arrest Survivors
An observational study of Cardiac Arrest (CA) and Hypoxic-Ischemic Brain Injury, run by Chungnam National University Hospital at 1 site in South Korea.
Trial summary
The goal of this observational study is to identify further pathophysiologic mechanism of secondary brain injury following cardiac arrest by using serial multiomics profiling of serum and cerebrospinal fluid (CSF) samples. The main question it aims to answer is: A. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury, Post-Resuscitation Syndrome
- How many people
- 15 participants
- Where
- 1 siteSouth Korea
- Study dates
- 22 Jul 2025to 31 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with an out-of-hospital cardiac arrest who underwent post-resuscitation care
Who may be able to join
- Age ≥ 18 years old
- Out-of-hospital cardiac arrest (OHCA)
- Patients who have received post-resuscitation care including temperature control due to unconsciousness (Glasgow Coma Score < 8) after sustained ROSC.
- Patients who consented to the placement of lumbar catheter for storing cerebrospinal fluid and blood samples in a human biobank.
Who cannot join
- Patients diagnosed with a central nervous system-related disease before cardiac arrest
- Patients who have undergone extracorporeal circulatory membrane oxygenation therapy
- Patients who died within 24 hours from post-resuscitation care
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Serial Multiomics Profiling Using Serum and Cerebrospinal Fluid Samples Following Out-of-hospital Cardiac Arrest: a Prospective Observational Study
The goal of this observational study is to identify further pathophysiologic mechanism of secondary brain injury following cardiac arrest by using serial multiomics profiling of serum and cerebrospinal fluid (CSF) samples. The main question it aims to answer is:
- The main question it aims to answer is: What are the dynamic molecular changes in serum and CSF that reflect the pathophysiological mechanisms of secondary brain injury after cardiac arrest? B. What are the differences in serum and CSF multiomic signatures between varying severities of cardiac arrest, and how are these differences associated with the underlying pathophysiological mechanisms of secondary brain injury?
Serum and CSF samples that have already been prospectively collected from participants and stored in the BioBank will be used for this analysis.
- Keywords
- cardiac arrest, hypoxic-ischemic brain injury, post-resuscitation syndrome, multiomics, cerebrospinal fluid
- Medical subject headings
- Heart Arrest, Hypoxia-Ischemia, Brain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| good neurologic outcome | Cerebral Performance Category (CPC) : 1 or 2 | |
| poor neurologic outcome | Cerebral Performance Category (CPC) : 3 to 5 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurological outcome
Neurological outcome is evaluated using the Cerebral Performance Category (CPC) scale. The CPC score ranges from 1 to 5, where 1 indicates good cerebral performance (normal/mild disability), 2 indicates moderate cerebral disability, 3 indicates severe cerebral disability, 4 indicates coma or vegetative state, and 5 indicates brain death. Higher scores represent a worse neurological outcome.
Measured: after 6 months from return of spontaneous circulation
Secondary outcomes (1)
Illness severity score of cardiac arrest (rCAST)
llness severity is assessed using the revised Post-Cardiac Arrest Syndrome for Therapeutic hypothermia (rCAST) score, which incorporates initial rhythm, blood pH, lactate levels, motor response, and arrest duration. The total score ranges from 0 to 15, with higher scores indicating greater illness severity and worse prognosis. Based on the total score, patients are categorized into three severity risk groups: low severity (0-5 points), moderate severity (6-8 points), and high severity (9-15 points), where the high-severity group reflects the worst clinical prognosis and highest risk of poor outcome.
Measured: immediately after return of spontaneous circulation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2025
- Study start22 Jul 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiac Arrest (CA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chungnam National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Changshin Kang, Chungnam National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07090577
- Sponsor's protocol ID
- CNUH-202507010
- Other IDs
- RS-2025-00554697
- Acronym
- MOPCAS
- Status last verified
- Sep 2026
- First submitted
- 21 Jul 2025
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared publicly due to ethical and privacy concerns. However, data sharing may be possible upon reasonable request with prior approval from the ethics committee and the principal investigator
Publications
You Y, Park JS, Min JH, Jeong W, Ahn HJ, In YN, Jeon SY, Lee JK, Kang C. Blood-brain barrier permeability for the first 24 hours in hypoxic-ischemic brain injury following cardiac arrest. Resuscitation. 2024 May;198:110150. doi: 10.1016/j.resuscitation.2024.110150. Epub 2024 Feb 23.
PubMed 38401708Stopa V, Lileikyte G, Bakochi A, Agarwal P, Beske R, Stammet P, Hassager C, Arman F, Nielsen N, Devaux Y. Multiomic biomarkers after cardiac arrest. Intensive Care Med Exp. 2024 Sep 27;12(1):83. doi: 10.1186/s40635-024-00675-y.
PubMed 39331333Lileikyte G, Bakochi A, Ali A, Moseby-Knappe M, Cronberg T, Friberg H, Lilja G, Levin H, Arman F, Kjellstrom S, Dankiewicz J, Hassager C, Malmstrom J, Nielsen N. Serum proteome profiles in patients treated with targeted temperature management after out-of-hospital cardiac arrest. Intensive Care Med Exp. 2023 Jul 17;11(1):43. doi: 10.1186/s40635-023-00528-0.
PubMed 37455296
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serial Multiomics Profiling Using Serum and Cerebrospinal Fluid Samples Following Out-of-hospital Cardiac Arrest: a Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07090577
- Acronym / sponsor ID
- MOPCAS / CNUH-202507010
- Keywords
- cardiac arrest, hypoxic-ischemic brain injury, post-resuscitation syndrome, multiomics, cerebrospinal fluid
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Chungnam National University HospitalUniversity, hospital or other
- Study start
- 22 Jul 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 29 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to identify further pathophysiologic mechanism of secondary brain injury following cardiac arrest by using serial multiomics profiling of serum and cerebrospinal fluid (CSF) samples. The main question it aims to answer is:
- The main question it aims to answer is: What are the dynamic molecular changes in serum and CSF that reflect the pathophysiological mechanisms of secondary brain injury after cardiac arrest? B. What are the differences in serum and CSF multiomic signatures between varying severities of cardiac arrest, and how are these differences associated with the underlying pathophysiological mechanisms of secondary brain injury?
Serum and CSF samples that have already been prospectively collected from participants and stored in the BioBank will be used for this analysis.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| good neurologic outcome | – | –Cerebral Performance Category (CPC) : 1 or 2 |
| poor neurologic outcome | – | –Cerebral Performance Category (CPC) : 3 to 5 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with an out-of-hospital cardiac arrest who underwent post-resuscitation care
Key inclusion criteria (4 listed)
- Age ≥ 18 years old
- Out-of-hospital cardiac arrest (OHCA)
- Patients who have received post-resuscitation care including temperature control due to unconsciousness (Glasgow Coma Score < 8) after sustained ROSC.
- Patients who consented to the placement of lumbar catheter for storing cerebrospinal fluid and blood samples in a human biobank.
Key exclusion criteria (3 listed)
- Patients diagnosed with a central nervous system-related disease before cardiac arrest
- Patients who have undergone extracorporeal circulatory membrane oxygenation therapy
- Patients who died within 24 hours from post-resuscitation care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Neurological outcome
Time frame: after 6 months from return of spontaneous circulation
Neurological outcome is evaluated using the Cerebral Performance Category (CPC) scale. The CPC score ranges from 1 to 5, where 1 indicates good cerebral performance (normal/mild disability), 2 indicates moderate cerebral disability, 3 indicates severe cerebral disability, 4 indicates coma or vegetative state, and 5 indicates brain death. Higher scores represent a worse neurological outcome.
1 secondary outcome
Illness severity score of cardiac arrest (rCAST)
Time frame: immediately after return of spontaneous circulation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Results publication: PubMed 38401708You Y, Park JS, Min JH, Jeong W, Ahn HJ, In YN, Jeon SY, Lee JK, Kang C. Blood-brain barrier permeability for the first 24 hours in hypoxic-ischemic brain injury following cardiac arrest. Resuscitation. 2024 May;198:110150. doi: 10.1016/j.resuscitation.2024.110150. Epub 2024 Feb 23.
- Results publication: PubMed 39331333Stopa V, Lileikyte G, Bakochi A, Agarwal P, Beske R, Stammet P, Hassager C, Arman F, Nielsen N, Devaux Y. Multiomic biomarkers after cardiac arrest. Intensive Care Med Exp. 2024 Sep 27;12(1):83. doi: 10.1186/s40635-024-00675-y.
- Results publication: PubMed 37455296Lileikyte G, Bakochi A, Ali A, Moseby-Knappe M, Cronberg T, Friberg H, Lilja G, Levin H, Arman F, Kjellstrom S, Dankiewicz J, Hassager C, Malmstrom J, Nielsen N. Serum proteome profiles in patients treated with targeted temperature management after out-of-hospital cardiac arrest. Intensive Care Med Exp. 2023 Jul 17;11(1):43. doi: 10.1186/s40635-023-00528-0.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared publicly due to ethical and privacy concerns. However, data sharing may be possible upon reasonable request with prior approval from the ethics committee and the principal investigator
Related trials for Cardiac Arrest (CA)
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
RecruitingObservational study
Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm
Cardiac Arrest (CA), Cardiogenic Shock
RecruitingObservational study
Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU
Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage
Not yet recruiting
The OXY-VENT Study
Cardiac Arrest (CA), Cardiopulmonary Resuscitation (CPR)
RecruitingObservational study
Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest
Cardiac Arrest (CA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Arrest (CA) and Hypoxic-Ischemic Brain Injury, run by Chungnam National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neurological outcome (time frame: after 6 months from return of spontaneous circulation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07090577, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.